SCHEMBL790069

SCHEMBL790069

C[C@@H](NS(=O)(=O)c1ccccc1)C(=O)O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 2/20 0.81
MMP2 P08253 4/20 0.66
MMP3 P08254 3/20 0.66
MMP13 P45452 3/20 0.66
MMP9 P14780 3/20 0.66
MMP1 P03956 2/20 0.66
MMP7 P09237 2/20 0.66
HSD17B10 Q99714 3/20 0.59
ALDH1A1 P00352 3/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
SLC1A3 P43003 2/20 0.57
SLC1A2 P43004 2/20 0.57
SLC1A1 P43005 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.54
HTT P42858 2/20 0.54
LMNA P02545 1/20 0.54
CA12 O43570 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL702794 1.00 ADAMTS4 (0.81) ADAMTS4MMP2MMP3MMP13MMP9
SCHEMBL702793 1.00 ADAMTS4 (0.81) ADAMTS4MMP2MMP3MMP13MMP9
Trifluoroacetic Acid SCHEMBL7346536 0.90 ADAMTS4 (0.68) ADAMTS4MMP2MMP3MMP13MMP9
SCHEMBL1751961 0.90 ADAMTS4 (1.00) ADAMTS4MMP2MMP3MMP13MMP9
SCHEMBL4651862 0.90 ADAMTS4 (1.00) ADAMTS4MMP2MMP3MMP13MMP9
SCHEMBL17318887 0.86 ADAMTS4 (0.62) ADAMTS4MMP2MMP3MMP13MMP9
SCHEMBL14217417 0.85 MMP9 (0.74) ADAMTS4MMP2MMP3MMP13MMP9
SCHEMBL6798909 0.85 ADAMTS4 (0.70) ADAMTS4MMP2MMP3MMP13MMP9
SCHEMBL791357 0.85 ADAMTS4 (0.61) ADAMTS4MMP2MMP3MMP13MMP9
SCHEMBL3687103 0.85 ADAMTS4 (0.61) ADAMTS4MMP2MMP3MMP13MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3653607-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPBAU E K (DE) 2023-10-18 EP claimed
EP-3653607-A2 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE Reuter Chemische Apparatenbau e.K. (DE) 2020-05-20 EP claimed
US-20160251311-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPARATEBAU KG (DE) 2016-09-01 US claimed
EP-2958894-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE Reuter Chemische Apparatebau KG (DE) 2015-12-30 EP claimed
WO-2014128139-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPARATEBAU KG (DE) 2014-08-28 WO claimed
CN-101180029-B Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin SHISEIDO CO LTD 2011-02-16 CN claimed
US-11897843-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine REUTER CHEMISCHE APPARATEBAU KG 2024-02-13 US disclosed
EP-4289819-A2 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE Reuter Chemische Apparatebau e.K. (DE) 2023-12-13 EP disclosed
EP-3653607-B1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPBAU E K (DE) 2023-10-18 EP disclosed
US-20230008387-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPARATEBAU KG (DE) 2023-01-12 US disclosed
US-11472770-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine REUTER CHEMISCHE APPARATEBAU KG 2022-10-18 US disclosed
EP-3653607-A2 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE Reuter Chemische Apparatenbau e.K. (DE) 2020-05-20 EP disclosed
US-20200087257-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE REUTER CHEMISCHE APPARATEBAU KG (DE) 2020-03-19 US disclosed
WO-2012037108-A1 AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
WO-2012037108-A1 AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
CN-101180029-B Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin SHISEIDO CO LTD 2011-02-16 CN disclosed
US-20090215893-A1 Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin SHISEIDO COMPANY LTD (JP) 2009-08-27 US disclosed
CN-101180029-A Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin SHISEIDO CO LTD (JP) 2008-05-14 CN disclosed
EP-1884230-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-02-06 EP disclosed
EP-1191024-A1 Thiadiazines and their use as inhibitors of metalloproteinases Tschesche, Harald (DE) 2002-03-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008387-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE NPEPPS, AASDHPPT, DNPEP ADAMTS4 4756/4885MMP2 4358/4885MMP3 3323/4885
US-11472770-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine NPEPPS, AASDHPPT, DNPEP ADAMTS4 4756/4885MMP2 4358/4885MMP3 3323/4885
US-11897843-B2 Process for the preparation of enantiomerically enriched 3-aminopiperidine NPEPPS, AASDHPPT, DNPEP ADAMTS4 4764/4885MMP2 4338/4885MMP3 3434/4885
US-20200087257-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE NPEPPS, AASDHPPT, DNPEP ADAMTS4 4756/4885MMP2 4358/4885MMP3 3323/4885
US-20090215893-A1 Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin CUTA, STOM, MTOR ADAMTS4 3345/4885MMP2 1673/4885MMP3 1827/4885
US-20160251311-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE NPEPPS, AASDHPPT, DNPEP ADAMTS4 4743/4885MMP2 4285/4885MMP3 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.